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Abstract
Open fractures are at risk of serious infection and, if 
infected, require several surgical interventions and courses 
of systemic antibiotics. We investigated a new injectable 
formulation that simultaneously hardens in vivo to form a 
porous scaffold for bone repair and delivers antibiotics at 
high concentrations to the local site of infection. Duration 
of antimicrobial activity against Staphylococcus aureus 
was determined using the serial plate transfer test. Ultimate 
compressive strength and porosity of the material was 
measured with and without antibiotics. The material was 
evaluated in vivo in an ovine medial femoral condyle defect 
model contaminated with S. aureus. Sheep were sacrificed 
at either 2 or 13 weeks and the defect and surrounding bone 
assessed using micro-computed tomography and histology. 
Antimicrobial activity in vitro persisted for 19-21 days. 
Sheep with antibiotic-free material and bacteria became 
infected, while those with antibiotic-containing material 
and bacteria did not. Similarly, new bone growth was seen 
in uninoculated animals with plain polymer, and in those 
with antibiotic polymer with bacteria, but not in sheep with 
plain polymer and bacteria. The antibiotic-impregnated 
scaffolds were effective in preventing S. aureus infections 
whilst supporting bone growth and repair. If translated into 
clinical practice, this approach might reduce the need for 
systemic antibiotics.
Keywords: PLGA; biodegradable scaffold; infection; in 
vivo; bone ingrowth.
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Introduction
Even with optimal management, the risk of infection 
is greater than 30 % in the most severe open fractures, 
with only 1-2 % of closed fractures becoming infected 
(Patzakis and Wilkins, 1989; Giannoudis et al., 2006; 
Zalavras et al., 2007). Treatment after initial surgical 
debridement often comprises the implantation and 
subsequent removal of antibiotic-impregnated beads in 
parallel with systemic broad-spectrum antibiotics before 
bone grafting can be carried out (Motsitsi, 2008). This 
is a lengthy and costly process, with 3.7 % of infections 
unsuccessfully treated (Ostermann et al., 1995). Current 
methods of local antibiotic delivery involve the use of 
non-biodegradable or biodegradable materials that are 
unsatisfactory for several reasons. Non-biodegradable 
materials include polymethylmethacrylate (PMMA) 
preformed beads consisting of gentamicin and antibiotic-
impregnated PMMA cement. While they deliver 
high local concentrations of antibiotics, they are not 
replaced with new bone and require a second surgery 
for removal (Stańczyk and van Rietbergen, 2004; Gogia 
et al., 2009). Biodegradable products on the market, 
for example gentamicin-impregnated collagen sheets 
and calcium sulphate, degrade too rapidly to support 
new bone growth (Hing et al., 2007), do not provide 
structural support (Carson and Bostrom, 2007) and 
contain only one antibiotic, encouraging development 
of bacterial resistance (Zhao and Drlica, 2002). A range 
of aerobic bacteria, in particular Staphylococcus aureus, 
Enterobacteria, Streptococcus species and anaerobes 
(Mader et al., 1999) may cause osteomyelitis, with the 
most commonly used antibiotic, gentamicin, inactive 
against anaerobic bacteria (Web Ref. 1). In order to extend 
the antimicrobial spectrum, and to prevent resistance, 
a combination of at least two antibiotics with different 
bacterial target sites should be used (Zhao and Drlica, 
2002). At the same time, considerations of chemical 
compatibility, release kinetics and potential for local 
toxicity, especially to osteoblasts, need to be taken into 
account. A combination of gentamicin and clindamycin 
would give activity against most of the expected bacterial 
contaminants including anaerobes.
 Injectable biodegradable scaffolds have many benefits 
including minimally invasive delivery and the ability to 
deliver drugs in vitro (Rahman et al., 2012; Gould et al., 
2013; Rahman et al., 2013) and drugs, cells and proteins 
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locally to the fracture site (Ginty et al., 2008; Kirby et al., 
2011). They have also been shown to reduce the length 
of hospital stay; need for rehabilitation, postoperative 
morbidity and readmission rate and consequently the 
associated costs are significantly reduced (Ilan and Ladd, 
2003). The scaffolds provide mechanical strength to the 
wound site and an osteoconductive matrix. Several factors 
have an effect on bone growth; especially scaffold porosity 
(Mastrogiacomo et al., 2006), pore size (Karageorgiou 
and Kaplan, 2005), pore interconnectivity, mechanical 
strength and degradation rate (Blokhuis et al., 2000). There 
is a trade-off between porosity and mechanical strength, 
which is thought to fall ideally within the biological range 
for human trabecular bone of 50-90 % porosity with pore 
sizes of at least 100 µm (Karageorgiou and Kaplan, 2005) 
and a compressive strength of 2-12 MPa (Lee and Shin, 
2007). The degradation rate of the bone graft material 
should match the rate of the bone growth for optimal bone 
regeneration (Vaccaro, 2002; Wenisch et al., 2003).
 An injectable material using poly(DL-lactic acid-co-
glycolic acid) (PLGA), which is a biodegradable synthetic 
polymer, with a long history of medical use (Anderson and 
Shive, 1997; Zolnik and Burgess, 2007) was evaluated. 
The degradation of the polymer particles can be altered 
by the modification of the lactide:glycolide ratio, the chain 
length and the addition of plasticisers (Jacobsen and Fritz, 
1999). The plasticiser PEG was added to alter the polymer’s 
thermal profile, resulting in the production of thermally 
sensitive particles. These harden into a solid porous 
structure at 37 °C, due to particles becoming adhesive and 
malleable at their glass transition temperature and adhering 
to each other Dhillon et al., 2011). The hydrophilic PEG 
begins to leach out of the particles causing a decrease in 
concentration and a concomitant increase in glass transition 
temperature, therefore allowing the particles to re-solidify 
to form a strong porous structure (France and Quirk, 2008). 
The resulting scaffolds support cell growth, as shown by 
their ability to support the growth of human mesenchymal 
stem cells for 7 days (Rahman et al., 2012). Gentamicin 
sulphate and clindamycin hydrochloride can be suspended 
in the liquid carrier and then become trapped within the 
pores of the scaffold as it hardens.
 In this study we explored the hypothesis that antibiotic 
impregnation of the biodegradable scaffold would prevent 
infection and support new bone growth in a bacterially 
contaminated bone defect.
Materials and Methods
Particle production
Poly (DL-lactic acid-co-glycolic acid) (PLGA 85:15 DLG 
4A, molecular weight 56 kDa, Lakeshore Biomaterials/
Evonik, Essen, Germany) was melt-blended with 
poly(ethylene glycol) 400 (PEG 400, Clariant, Leeds, UK) 
using a heating mantle at 110-120 °C and a Silverson high 
shear mixer, to produce a blend of 93.5 % PLGA and 6.5 % 
PEG 400 (w/w).
 The blend was ground into particles, after cooling with 
liquid nitrogen, using a bench top grinder (F203, Krups, 
Liverpool, UK). An AS 200 Sieve Shaker (Retsch, Haan, 
Germany) was used to collect the 100-200 µm fraction.
 The final powder contained 90 % of the blend (PLGA 
and PEG 400) dry-mixed with 10 % of 100-200 µm β-tri-
calcium phosphate w/w (β-TCP, Plasma Biotal, Buxton, 
UK). This was then sterilised with electron beam radiation 
at 25-30 kGy (Isotron, Daventry, UK).
Carrier production
To form a paste the particles were mixed with 0.5 % 
medium viscosity sodium carboxymethyl cellulose (CMC, 
Blanose, Ashland, Covington, KY, USA) dissolved in 
0.9 % saline (B. Braun, Sheffield, UK) at a ratio of 1 g of 
powder to 0.8 mL of liquid. The CMC had a viscosity 
of 400-800 cps, a substitution range of 1.15-1.45 and 
a sodium content of 10.5-12 %. The CMC solution was 
previously steam-sterilised at 121 °C for 15 min. For 
test samples, the antibiotics were suspended in the CMC 
solution before mixing with the powder.
Scaffold preparation
Scaffolds were prepared for strength, porosity and serial 
plate transfer tests using 6 mm x 12 mm cylindrical PTFE 
moulds. After the mould was filled with the polymer paste, 
it was placed in a sealed polythene bag for 2 h in a cell 
culture incubator maintained at 37 °C, to simulate body 
conditions of temperature and humidity. For strength and 
porosity testing, the moulds were additionally placed 
in 0.9 % saline at 37 °C for 24 h. The 2 and 24 h time 
points were selected due to the initial setting and the final 
hardening of the scaffold, respectively.
In vitro porosity
After sintering for 24 h and freeze-drying for 12-18 h, the 
porosity of the in vitro scaffolds was calculated using both 
the Archimedes’ Principle of Mass Displacement Equation 
(eqn. 1) and micro-computed tomography.
 A high-resolution Skyscan micro X-ray computed 
tomography system (micro-CT, Skyscan 1174, Skyscan, 
Kontich, Belgium) was used to determine porosity within 
the scaffolds. Scanning was carried out at a voltage 
of 50 kV, current of 800 mA and a voxel resolution of 
14.7 µm. The transmission images were reconstructed using 
Skyscan supplied software (NRecon).
 To distinguish between solid material and porous 
regions a single threshold value was applied and a second 
threshold value (255/20) was selected to segment the pores 
from surrounding scaffold material.
   (1)
Mechanical testing
Unconstrained uniaxial compression testing was carried 
out on both antibiotic-impregnated and control scaffolds. 
A TA.HD+ texture analyser fitted with a Peltier chamber 
(Stable Microsystems, Godalming, UK) was used with a 
10 mm compression probe, a 50 kg load cell and a test 
speed of 0.04 mm/sec at 37 °C. Young’s modulus and the 
ultimate compressive strength were calculated. Fifteen min, 
2 h and 24 h time points were assessed to check scaffold 
setting time.
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Serial Plate Transfer Test
The Serial Plate Transfer Test (SPTT) was used to monitor 
antimicrobial activity and also the duration of antibiotic 
release from the scaffold material that was to be used in 
the in vivo study (Bayston et al., 2009).
 Plates of Iso-Sensitest Agar (ISA, Oxoid, Basingstoke, 
UK) were inoculated, using a sterile swab, with a 
suspension of bacteria (S aureus) of opacity equivalent to 
0.5 MacFarland Standard (1x108 colony-forming units/
mL). Scaffolds with and without antibiotics were placed 
in the centre of an agar plate (n = 3) and incubated for 18-
24 h at 37 °C. The zones of inhibition (zone diameter minus 
scaffold diameter in mm) were measured using digital 
callipers. Scaffolds were transferred daily to a fresh seeded 
plate, ensuring that the same scaffold surface was in contact 
with the agar, until a zone of inhibition was no longer 
seen. Any antibiotic impregnated scaffolds that ceased to 
produce a ZOI were split in half lengthways, placed onto 
seeded agar plates with the flat surface in contact with the 
agar and incubated overnight at 37 °C, to ensure that no 
further antibiotics were being released.
Test bacterium
The strain of S. aureus used in this study was a clinical 
isolate (F2789) obtained from an infected human knee 
arthroplasty at revision surgery. Characterisation was 
carried out by conventional methods: gram stain, catalase 
production, DNAse production, antibiotic susceptibilities 
(in accordance with the British Society for Antimicrobial 
Chemotherapy Guidelines (Web Ref. 2)), biochemical 
profiling (API, BioMérieux, Basingstoke, UK) and 
minimum inhibitory concentration (MIC, Etest, AB 
Biodisk, Solna, Sweden).
Antibiotics
The antibiotic combination tested was 4 % gentamicin 
sulphate w/v (Sigma-Aldrich) and 2.5 % clindamycin 
hydrochloride w/v (Pfizer, Tadworth, UK). These antibiotic 
concentrations were selected as they are similar to what 
is already in routine use in bone cements, for example 
Refobacin Revision Cement (BIOMET, Malmö, Sweden) 
and Copal G + C Revision Cement (Heraeus Medical, 
Newbury, UK), and together cover the majority of bacteria 
involved in osteomyelitis.
 The antibiotics were suspended in the carrier (0.5 % 
medium viscosity CMC dissolved in 0.9 % saline) that 
was used to form the polymer paste.
Scaffold drug content
The total antibiotic content was measured in crushed 
antibiotic impregnated scaffolds that had been releasing 
antibiotics on an SPTT for up to 21 days. Clindamycin was 
measured using High Performance Liquid Chromatography 
(HPLC) whilst gentamicin was detected with an ADVIA 
Centaur Gentamicin assay (Siemens, Erlangen, Germany).
 For the detection and quantification of Clindamycin 
hydrochloride, RP-HPLC analysis was performed on an 
Agilent 1100 HPLC machine with a variable wavelength 
UV detector (HPLC - UV) (Agilent Technologies, 
Berkshire, UK) connected to a Chemstation operating 
software system. Chromatographic separations were 
performed on an Eclipse XDB-C8 (5 µm, internal diameter 
(i.d.) 4.6 mm x 150 mm) column (Agilent Technologies). 
Column temperature was 40 °C, the volume of injection 
was 100 μL and the flow rate was 1.0 mL/min.
 A gradient was used to detect clindamycin and the 
mobile phase consisted of aqueous sodium dihydrogen 
phosphate (15 mM, pH 2.5, Sigma-Aldrich) with 
10 % acetonitrile and methanol (Fisher Scientific, 
Loughborough, UK).
 Gentamicin levels were detected using the ADVIA 
Centaur Gentamicin assay, which is a competitive 
immunoassay using direct, chemiluminescent technology. 
The sample competes with acridinium ester-labelled 
gentamicin derivative in the reagent for a limited amount 
of monoclonal mouse anti-gentamicin antibody, which 
is coupled to paramagnetic particles. There is an inverse 
relationship between the amount of gentamicin and the 
amount of relative light units detected by the system.
In vivo model and surgery
Thirty female non-pregnant skeletally mature (age 4-5 
years, weight 53-74 kg) English Mule sheep were used. 
All procedures were carried out in compliance with United 
Kingdom Home Office regulations (Animal Scientific 
Procedures Act, Web Ref. 3). Animals were screened, to 
ensure good physical condition and were acclimatised to 
the new environment for a minimum of 7 days prior to 
surgery. After surgery, animals were housed in individual 
pens for 4 days and then they were housed in a group 
barn. At two weeks, the sutures were removed and the 
sheep were put out to pasture. Prior to surgery food was 
withheld for a minimum of 12 h, but water was available 
ad libitum. Sheep were assigned randomly to 5 different 
treatment groups (Table 1). These were an infection and 
Group
1 (n = 6)
Group
2 (n = 6)
Group
3 (n = 6)
Group
4 (n = 6)
Group
5 (n = 6)
Bacteria added 
at surgery S aureus (F2789) S aureus (F2789) None None S aureus (F2789)
Antibiotics 
within scaffold None
4 % Gentamicin + 
2.5 % Clindamycin None None
4 % Gentamicin + 
2.5 % Clindamycin
Sacrifice time-
point 2 weeks 2 weeks 2 weeks 13 weeks 13 weeks
Table 1. Different treatments for the 5 groups of sheep.
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scaffold group sacrificed at 2 weeks, a scaffold only group 
sacrificed at 2 weeks and 13 weeks and an infection and 
scaffold with antibiotics group sacrificed at 2 and 13 weeks.
 The sheep were pre-medicated intramuscularly with 
2 % Rompun (0.1 mg/kg Xylazine, Bayer, Newbury, UK). 
Anaesthesia was induced with Ketaset (Ketamine, 2 mg/
kg, Fort Dodge Animal Health Ltd, Southampton, UK) and 
2.5 mg Hypnovel (Midazolam, Roche Products, Welwyn 
Garden City, UK), and then maintained with 2 % Isoflurane 
(Abbott Laboratories, Maidenhead, UK) in 100 % oxygen. 
Pre- and post-operative analgesia was given by means of 
sustained release Durogesic 75 µg/hr patches (Fentanyl, 
2 patches 12 h before surgery and 2 patches 60 h after 
surgery, Janssen-Cilag, Saunderton, UK). No prophylactic 
antibiotics were given either pre- or post-operatively, as this 
would have invalidated the results. For surgery, the animals 
were placed in left lateral recumbency to access the medial 
aspect of the left hind leg. The area was then clipped and 
prepared using aqueous povidone iodine antiseptic solution 
(Vetasept, Medivet Professional, Hayes, UK), with an 
antiseptic swab covering the site until surgery commenced. 
Once in theatre, the area was thoroughly washed with 
Hydrex chlorhexidine (Ecolab, Swindon, UK).
 The surgical site was incised and a drill hole was made 
in the cancellous bone of the medial femoral condyle in 
the left hind leg. The cylindrical hole was 8 mm diameter 
x 15 mm deep and created by drilling a pilot hole which 
was enlarged using a custom calibrated reamer to create a 
standardised defect (Fig. 1a). In the ovine cancellous bone 
defect model a critical size defect has been published at 
a diameter of 5.1-10 mm (Nuss et al., 2006; Bodde et al., 
2007; Pearce et al., 2007; van der Pol et al., 2010), and a 
height of 10-15 mm (Walsh et al., 2003; Patel et al., 2005; 
Nuss et al., 2006; van der Pol et al., 2010; Ding et al., 
2012) within which our defect lies. Culture swabs were 
taken after the initial skin incision and bone was also taken 
from within the defect to ensure that the sheep were free 
of infection at the time of surgery. In scaffold-only sheep, 
the defect was dried using a sterile swab and the scaffold 
material (approximately 0.75 g) was lightly packed into 
the defect (Fig. 1b). For the infection groups 20 µL of a 2 
x 106 cfu/mL suspension (40,000 cfu) of S. aureus (F2789) 
in sterile phosphate buffered saline (Oxoid) was inoculated 
into the defect, before packing with scaffold material 
(approximately 0.75 g of scaffold either with or without 
0.03 g gentamicin sulphate and 0.019 g of clindamycin 
hydrochloride). The subcutaneous tissue was closed using 
resorbable material (Vicryl 2-0, Ethicon, Kirkton, UK), 
whilst skin was closed with non-absorbable nylon sutures 
(Ethilon 0, Ethicon). A moisture vapour-permeable spray 
dressing (Opsite, Smith & Nephew Healthcare, Hull, UK) 
was then applied over the wound to protect it.
 The sacrifice time points were 2 weeks and 13 weeks. 
The 2-week time point was chosen in order to ensure that 
a localised infection had been created and also that the 
antibiotics were effective when combined with the scaffold 
material. By 13 weeks, it was expected that significant 
bone growth should have occurred due to the rate of bone 
remodelling and also the degradation rate of the scaffold 
material. The sheep were sacrificed using an overdose 
of barbiturate (Pentobarbital solution 20 %, 0.7 mg/kg, 
Pharmasol, Andover, UK). Immediately before sacrifice, 
intravenous blood samples were taken for aerobic and 
anaerobic culture. After sacrifice, tissue removal was 
carried out aseptically. Swabs, soft tissue and a sample from 
within the defect were collected for culture and histological 
processing. The femoral condyle was then removed and 
split using a saw with saline irrigation. The two halves 
were then fixed in 10 % neutral buffered formalin solution 
(NBF, Sigma-Aldrich), for 48 h at room temperature.
Culture of blood and tissue samples
Swabs were plated onto blood agar plates (Oxoid), and 
incubated aerobically and anaerobically for up to 48 h. 
The blood samples were inoculated into blood culture vials 
(BD Bactec™ Lytic/10 Anaerobic F and Plus+ Aerobic F, 
Oxford, UK) and incubated for 7 days at 37 °C. A sample 
was then taken from each bottle and plated on blood agar 
plates for incubation aerobically and anaerobically for up 
to 7 days. Bone and tissue samples were vortexed in PBS 
and the suspension plated onto blood agar, and incubated 
aerobically and anaerobically for up to 48 h. If bacterial 
growth occurred isolates were characterised to compare 
with the inoculum.
Micro-computed tomography
A high-resolution Skyscan micro X-ray computed 
tomography system (micro-CT, Skyscan 1174) was used to 
Fig. 1. (a) Image of defect drilled into the femoral condyle of a sheep. (b) Defect filled with scaffold material.
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determine bone ingrowth, porosity, pore size and trabecular 
thickness within femoral condyles. After fixing in 10 % 
NBF for 48 h at room temperature, bone was wrapped in 
cling film to prevent the sample from drying out and then 
mounted on the stage within the imaging system. Due to 
sample size and type, scanning was carried out at a voltage 
of 50 kV, current of 800 µA and a voxel resolution of 
32.4 µm. A 0.75 µm aluminium filter was also applied. 
The transmission images were reconstructed using Skyscan 
supplied software (NRecon).
 To distinguish between solid material and porous 
regions, a single threshold value was applied and a second 
threshold value (255/75) was selected to segment bone 
from surrounding tissue. Background noise in the images 
was reduced, by removing black and white speckles of 
less than 100 voxels. Analysis of bone volume was carried 
out on a set volume of interest of 5 x 1010 µm3 which was 
located 5 mm from the top of the defect and against the 
internal edge of the drilled defect. Quantitative analysis of 
porosity and pore architecture was obtained using direct 
morphometry calculations in the Skyscan CTAn software 
package.
Bone histology
The femoral condyle was fixed in 10 % NBF solution 
for 48 h at room temperature. One half of the condyle 
was then placed in 10 % ethylenediaminetetraacetic acid 
(EDTA, Sigma Aldrich) for decalcification. At two-weekly 
intervals, the bone samples were placed in a faxitron 
cabinet x-ray system (Model 43855C, Faxitron Bioptics, 
Tucson, AZ, USA) to assess the level of decalcification. 
This was judged to be complete at 26 weeks, after no 
mineralised bone could be detected by the faxitron.
 Samples were soaked in a 30 % sucrose solution 
(Sigma-Aldrich) for 24 h and then OCT embedding 
medium (Sakura Finetek UK, Thatcham, UK) for a further 
24 h before cryosectioning. Samples were mounted on 
cryostat chucks using OCT embedding medium. The 
sections were cut at -16 to -18 °C on a Leica CM1300 
(Leica Microsystems, Milton Keynes, UK). The Cryo-
Jane Tape Transfer System (Leica Microsystems) was 
used to collect the sections. A cold tape window was placed 
on the exposed block face and pressed down with a roller. A 
tungsten carbide blade was used without the antiroll plate 
to give 20 µm sections. The tape-mounted sections were 
then placed section downward onto a 4x adhesive coated 
slide and rolled to ensure contact. The slide was then cured 
with a UV lamp, and the tape window removed.
 Sections were then stained with a Modified Tetrachrome 
Method (Ralis and Watkins, 1992), which involves staining 
with Weigert’s haematoxylin, aniline blue, ponceau 
mixture and picro-orange. A Nanozoomer (Nanozoomer 
2.0 HT, Hamamatsu, Hamamatsu, Japan) was used to 
image the entire sections at 20x and 40x magnification, 
and viewed using the NanoZoomer Digital Pathology 
program. The number of specimens evaluated per group 
was- Group 1 = 1; Group 2 = 3; Group 3 = 3; Group 4 = 6; 
Group 5 = 6. Further images were taken using a Qimaging 
MicroPublisher 3.3RTV camera attached to Leica DM4000 
B microscope and accompanying software (OpenLab).
Soft tissue histology
Soft tissue samples were fixed in 10 % NBF, processed 
into paraffin wax and stained with Weigert’s Haematoxylin 
and Eosin.
Statistical analysis
Statistical analysis was carried out using one-way analysis 
of variance (ANOVA, Minitab® 16.1.0, Coventry, UK). 
p-values of ≤ 0.05 were considered to be significant. A 
Fisher’s Least Significant Difference post-hoc test was 
used to investigate individual differences.
Results
Micro-organism characterisation and sensitivities
The API profile of F2789 was 6336151 and the numerical 
antibiogram (Bayston et al., 2009) was 44004. This showed 
that F2789 was a strain of S. aureus susceptible to, amongst 
others, gentamicin and clindamycin. The minimum 
inhibitory concentrations (MIC) were 0.094 mg/L for 
gentamicin and 0.064 mg/L for clindamycin.
Fig. 2. The duration of antimicrobial 
activity of scaffolds containing 
4 % gentamicin sulphate and 2.5 % 
clindamycin hydrochloride, tested 
against S. aureus (F2789).
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Serial Plate Transfer Test (SPTT)
Antimicrobial activity declined steadily over a 19 ± 2 day 
period, as can be seen in Fig. 2. No zones of inhibition 
were observed around scaffolds that were not impregnated 
with antibiotics. The bacteria did not become resistant to 
the antibiotic combination over the duration of the release.
Drug content of scaffold (Fig. 3)
The total content of both gentamicin and clindamycin 
within scaffolds show a significant drop over the 21 day 
period, with most of the antibiotics released over the first 
7 days. Less than 1 % of the antibiotics were remaining 
at 21 days.
 The lower than expected level of gentamicin is 
possibly due to the potency of the antibiotics. Gentamicin 
sulphate has a potency of 590 µg/mg, whilst the potency 
of clindamycin is 900 µg/mg.
Mechanical properties
Compression testing of scaffolds was carried out after 
15 min, 2 h and 24 h of sintering both with and without 
antibiotic combination. The maximum compressive 
strength and Young’s Modulus increased significantly 
from a 15 min sinter to a 24 h sinter in all groups 
(p = 0.010 and p = 0.012, respectively). Within each time 
point, there were no differences in the strength of scaffolds 
with and without antibiotics (Fig. 4 and 5).
 To assess porosity the scaffolds were sintered for 24 h 
and analysed using both micro-computed tomography 
and the Archimedes Mass Displacement Equation. The 
scaffolds had a significantly higher value using the 
Archimedes equation as the micro-CT scanning resolution 
used precluded the detection of microporosity within the 
scaffolds. There were no significant differences between 
scaffold porosity within methods, either with or without 
antibiotics (Table 2).
In vivo study (Table 3)
The sheep model was selected, as sheep have been used 
in the study of numerous musculoskeletal conditions and 
diseases including biomaterial evaluation (Martini et al., 
2001; Nuss et al., 2006). Although sheep cortical bone 
has fewer Haversian canals than human bone, the rate of 
bone healing approximates human values, with a similar 
pattern of bone ingrowth into porous implants over time 
(Pearce et al., 2007).
 Group 1 sheep that were inoculated with bacteria and 
that did not receive antibiotics in the scaffold showed a 
significantly greater weight loss than the sheep in Groups 
2-5 (p ≤ 0.001) and required analgesia for the duration of 
the study to alleviate lameness. Samples (approximately 
1 mm3) and swabs collected from within the defect and 
surrounding soft tissue contained approximately 105 cfu 
of bacteria per total sample, which were indistinguishable 
from the original strain (F2789) on re-characterisation 
using biochemical profiling and antibiograms. In all 
groups, no bacteria were cultured from the blood – which 
confirmed that the infection was localised to the bony 
defect and surrounding area, and was not systemic.
 The defects in Groups 2 and 5 were inoculated with 
S. aureus, but filled with antibiotic-impregnated scaffold 
material. At both sacrifice time points no bacteria were 
Fig. 3. Total gentamicin and 
clindamycin content (mg/L) 
of scaffolds determined by 
i m m u n o a s s a y  a n d  H P L C 
respectively.
Method of porosity analysis (%) ± SD
Archimedes’ Principle of Mass 
Displacement Equation Micro-computed tomography
Scaffold without antibiotics (n = 4) 56.68 ± 3.13 29.12 ± 7.26
Scaffold with antibiotics (n = 4) 54.36 ± 3.20 33.03 ± 8.55
Table 2. In vitro porosity results.
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Group 1 
(n = 6)
Bacteria and
control scaffold
(2 week sacrifice)
Group 2 
(n = 6)
Bacteria and 
antibiotic
impregnated
scaffold
(2 week sacrifice)
Group 3 
(n = 6)
Scaffold only 
control
(2 week sacrifice)
Group 4 
(n = 6)
Scaffold only 
control
(13 week sacrifice)
Group 5 
(n = 6)
Bacteria and 
antibiotic
impregnated
scaffold
(13 week sacrifice)
Pain relief
post-operatively 2 weeks 3 days 3 days 3 days 3 days
Lameness,
swelling and
increased
respiration rate
Yes No No No No
Weight change at 
sacrifice
- 7.8 kg + 6.2 kg + 5.8 kg + 8.8 kg + 14.3 kg
Bacteria present at 
sacrifice
S aureus (F2789) None None None None
Table 3. Results from the in vivo study.
Fig. 4. The Young’s 
Modulus of scaffolds 
containing antibiotics 
(4  % gen tamic in 
s u l p h a t e  a n d 
2.5 % clindamycin 
hydrochloride) after 
sintering for 15 min, 
2 h or 24 h.
Fig. 5. The ultimate 
compressive strength 
of scaffolds containing 
a n t i b i o t i c s  ( 4  % 
gentamicin sulphate 
and 2.5 % clindamycin 
hydrochloride) after 
sintering for 15 min, 
2 h or 24 h.
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found in the defect or surrounding tissue. Group 3 and 4 
sheep had defects filled with control scaffold material and 
were not inoculated with bacteria. There was no significant 
difference in weight gained in Groups 2-5, and these sheep 
required only minimal analgesia.
Micro-computed tomography (micro-CT) (Figs. 6 
and 7, and Table 4)
The introduction of S. aureus and control scaffold without 
antibiotics lowered bone volume in the area surrounding 
the defect, compared to sheep that received S. aureus and 
the antibiotic-impregnated scaffold. This was due to the 
bone infection breaking down the surrounding bone, and 
the expulsion of the scaffold material during harvesting 
(Fig. 6a).
 There was no significant difference in bone growth 
between sheep sacrificed at 2 weeks with (Group 2, Fig. 
6b) or without antibiotic-containing scaffold (Group 3, 
Fig. 6c), or sheep sacrificed at 13 weeks without (Group 
4, Fig. 6d) or with antibiotic-containing scaffold (Group 
5, Fig. 6e). The edge of the defect was clearly visible in 
Figs. 6b–6e, with new bone visible in Figs. 6d and 6e.
 Sheep sacrificed at 13 weeks had significantly more 
bone than sheep sacrificed at 2 weeks (p ≤ 0.001). There 
was no significant difference in the bone fill of defects 
in any group at 2 weeks. At 13 weeks the defect fill 
in sheep that received the antibiotic-free scaffold was 
68.4 ±13.0 % and sheep that received the antibiotic 
impregnated material and sacrificed at 13 weeks (Group 
5) were not significantly different and had a defect fill of 
53.8 % ±17.2 % (Fig. 7).
 At 13 weeks no scaffold material remained within the 
defects, as it had fully degraded. Therefore, the porosity and 
pore sizes of the scaffold material in vivo were calculated 
from sheep sacrificed at 2 weeks with (Group 2) and 
without antibiotics (Group 3) (Table 4). There was no 
significant difference in the initial percentage porosity of 
the scaffold material with and without antibiotics, which 
was 24.2 ±9.5 % and 26.4 ±5.1 %, respectively. Scaffold 
pore size was not significantly different between Group 
2 (201.2 ±21.4 µm) and Group 3 (186.2 ±23.9 µm). The 
Fig. 6. Micro-CT images of bone defects (half of defect 4 x 15 mm) with dotted line depicting the defect site. (a) 
Defect from the bacteria with antibiotic-free scaffold group (Group 1) showing bone lysis caused by the infection. 
The 10 % ceramic component can be seen as speckling within the defect, although in this group the product has been 
poorly retained. (b) Defect from sheep that received bacteria and the antibiotic-impregnated material and sacrificed 
at 2 weeks (Group 2). (c) Defect from control sheep sacrificed at 2 weeks (Group 3) showing clear edge of a fully 
packed defect and 10 % ceramic composition of the scaffold material. (d) Control sheep sacrificed at 13 weeks (Group 
4) and (e) defect from sheep sacrificed at 13 weeks with bacteria and antibiotic-impregnated scaffold (Group 5) with 
new bone filling the defect space.
Table 4. The porosity and pore size of the scaffold 
material within the bone defect of a sheep at 2 weeks.
Porosity (%) ± SD Pore size (µm) ± SD
Group 2
(Bacteria and 
antibiotic 
impregnated 
scaffold, n = 6)
24.21 ± 9.46 201.22 ± 21.44
Group 3
(Scaffold only 
control, n = 6)
26.40 ± 5.10 186.16 ± 23.91
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porosity for both in vivo and in vitro scaffolds was not 
significantly different when scanned using micro-CT 
(Tables 2 and 4).
Bone histology
A modified tetrachrome method (Ralis and Watkins, 1992) 
was employed to detect the different structures in the 
harvested femoral condyles.
 Group 1 (Bacteria and control scaffold at 2 weeks, Fig. 
8). Bone surrounding the defect had broken down due to 
the infection, and fragments were filling the defect space, 
which was left empty when the scaffold material was not 
retained at sacrifice. A large amount of fibrous tissue could 
be seen filling the defect.
 Groups 2 (2 week sacrifice with bacteria and antibiotic 
impregnated scaffold, Fig. 9) and 3 (2 week scaffold 
Fig. 7. Percentage bone 
fill of a specific volume 
of interest within the bone 
defect.
Fig. 8. Ralis tetrachrome staining within a bone defect in the femoral condyle of a sheep that was infected and did 
not receive antibiotics (Group 1) and sacrificed at 2 weeks. The defect is partially filled with the scaffold material. 
Sections b (originally, 1.25x magnification) and c (originally, 1.25x magnification) show the fibrous tissue (blue) 
that has formed due to the bone infection and the bone that is being broken down (red/black).
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Fig. 9. Ralis tetrachrome staining within a bone defect in the femoral condyle of a sheep sacrificed at 2 weeks with 
bacteria and antibiotic impregnated scaffold (Group 2). Section b (originally, 1.25x magnification) shows the polymer 
in contact with the edge of the bone defect and c (originally, 20x magnification) shows areas of osteoid (dark blue) 
which will in turn lead to new bone formation.
Fig. 10. Ralis tetrachrome staining within a bone defect in the femoral condyle of a control scaffold sheep sacrificed 
at 2 weeks (Group 3). Section b (originally, 2.5x magnification) shows the polymer remaining within the defect and 
c (originally, 5x magnification) shows areas of osteoid (dark blue) on the edges of the defect.
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control, Figs. 10 and 11). The edge of the defect was clearly 
visible with organised trabeculae, and scaffold material 
filling the majority of the defect. New bone could be seen 
forming at the edge of the defect. An osteoid layer was 
seen at the edges of the mature lamellar bone and at the 
mineralisation front.
 Groups 4 (13 week scaffold control, Fig. 12) and 5 
(13 week sacrifice with bacteria and antibiotic impregnated 
scaffold, Fig. 13).
 No polymer was remaining within the defect at 13 
weeks, and any area of the defect not filled with new 
bone contained soft tissue. The soft tissue was identified 
as cartilage that would be expected to eventually turn into 
mineralised bone. The edges of the original defect were 
clear and showed the different structures of new and old 
bone. At the interface of the new bone and soft tissue, there 
was a thick osteoid layer.
Soft tissue histology
Inflammatory cells, mainly macrophages, were observed in 
the soft tissue surrounding the defect site in all 5 groups as 
observed by others (Anderson and Shive, 2012).
Discussion
The biodegradable antibiotic-impregnated scaffold 
material was effective at preventing infection, whilst 
allowing new bone growth in a large animal bone defect 
model (8 mm diameter x 15 mm height).
 The scaffold material described here showed a gradual 
release of antibiotics, with 50 % of the antimicrobial 
activity present at Day 7 and 20 % present at Day 15 
as shown by SPTT (Fig. 2). It has been suggested that 
antibiotic concentration should be above the MIC for a 
Fig. 11. Image taken using a light microscope 
(originally, 5x magnificiation) of the centre of the defect 
containing polymer in a control scaffold sheep sacrificed 
at 2 weeks (Group 3).
Fig. 12. Ralis tetrachrome staining demonstrating new bone ingrowth within a bone defect in the femoral condyle of a 
control scaffold sheep sacrificed at 13 weeks (Group 4). No scaffold material was remaining within the defect. Section 
b (originally, 2.5x magnification) shows the comparison of new and old bone and c (originally, 10x magnification) 
shows different areas of osteoid (dark blue), new bone (brown) and calcified cartilage (pink red).
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minimum of 7 days for effective prevention of infection 
(Campoccia et al., 2010). No zones of inhibition were seen 
after Day 21. Fracture of the remaining polymer and testing 
for zones of inhibition showed no residual activity (results 
not shown), indicating that if any antibiotics remained in 
the polymer they were below the MIC of the test bacteria. 
Previous work has shown that the release of antibiotics 
from non-biodegradable bone cements and beads peaks 
at Day 1 (Nandi et al., 2009), but continues to be released 
at sub-inhibitory levels for several months (Henry et al., 
1991), with residual antibiotics found after 5 years in situ 
(Neut et al., 2003).
 The antibiotics tested here were gentamicin sulphate 
and clindamycin hydrochloride, which are routinely used 
in the treatment of bone infection with cement spacers, 
due to their heat stability and hydrophilic nature (Gogia 
et al., 2009). Although systemic gentamicin sulphate has 
been shown to be potentially nephrotoxic and ototoxic 
(Smith et al., 1980), local delivery allows for significantly 
higher doses of the antibiotic to be delivered to the infected 
site, whilst avoiding the issue of systemic toxicity, when 
compared to the systemic administration of antibiotics 
(Gitelis and Brebach, 2002). The results shown here 
suggest that such an approach might be translatable into 
clinical practice, by preventing an infection starting and 
therefore reducing the use of long courses of systemic 
antibiotics required to treat infection with the concomitant 
risks of resistance and adverse effects.
 A combination of antibiotics was used to further 
reduce the risk of resistance arising at the defect site. 
This approach has been shown to prevent resistance, 
as two concurrent mutations are required for bacterial 
survival when two antibiotics of different classes are 
each maintained at levels above their minimum inhibitory 
concentrations (Eliopoulos and Eliopoulos, 1988; Fantin 
and Carbon, 1992; Gould, 1999; Zhao and Drlica, 2001). 
The combination of gentamicin sulphate and clindamycin 
hydrochloride has been shown to have an antimicrobial 
effect on more than 90 % of bacteria common to infected 
arthroplasties (Kuhn, 2000) and is more effective in 
preventing biofilm formation than bone cements with 
gentamicin alone (Neut et al., 2005). The combination 
can be expected to have activity against gram-positive 
bacteria (e.g. staphylococci), gram-negative bacteria (e.g. 
Escherichia coli) and anaerobes (e.g. Bacteroides spp).
 The addition of the antibiotic combination did not 
significantly affect the compressive strength or the porosity 
of the material. Unlike the material investigated in this 
study, there is a large variation in the mechanical properties 
of bone cements after the addition of antibiotics (Dall 
et al., 2007; Lewis, 2008; Hsieh et al., 2009). Porosity 
is determined by the method of mixing, which has a 
significant effect on the rate of antibiotic release (Neut et 
al., 2007; Web Ref. 4).
 Bone defects in groups 1, 2 and 4 were inoculated 
with 20 μL of 2 x 106 cfu/mL of S. aureus, using a method 
Fig. 13. Ralis tetrachrome staining demonstrating the new bone ingrowth in a bone defect in the femoral condyle of 
a sheep that received bacteria, antibiotic impregnated scaffold and was sacrificed at 13 weeks (Group 5). No scaffold 
material was remaining within the defect. The edges of the original defect are clear. Sections b (originally, 1.25x 
magnification) and c (originally, 2.5x magnification) show different areas of osteoid (dark blue), new bone (brown) 
and calcified cartilage (pink red).
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described by Beardmore et al. (2005). All sheep that were 
inoculated with S. aureus and did not receive antibiotics 
within the scaffold material showed clinical signs of a 
localised bone infection, and bone lysis was observed on 
the micro-CT images. At sacrifice, the same strain of S. 
aureus was cultured from samples collected from within the 
defect and surrounding tissue. Therefore, with the addition 
of antibiotics to the material it was possible to prevent bone 
infection. Although S. aureus is the most common isolate, 
a range of different bacteria can cause bone infection 
(Mader et al., 1999). As this study investigated the efficacy 
of the scaffold material only against S. aureus, further 
investigations are needed to determine the activity of the 
material when challenged by other bacteria or by more 
than one species at the same time.
 By 13 weeks the bone defects drilled in experimental 
or control femoral condyles and packed with the scaffold 
either with or without antibiotics, were over 60 % full. The 
scaffold material had fully degraded at 13 weeks, as was 
seen by Schmidt et al. (1995) in the subcutaneous pouches 
of rats. Ideally, the degradation rate of bone graft material 
should match the rate of the bone growth (Vaccaro, 2002; 
Wenisch et al., 2003).
 PLGA degrades into lactic acid and glycolic acid, which 
are removed by the body’s normal metabolic pathways 
(Wu and Ding, 2004). The degradation products reduce the 
pH in the vicinity of the scaffold material (Li and Chang, 
2005) and this can result in an inflammatory response. This 
is often clinically insignificant, and less likely to arise with 
porous implants as degradation products do not accumulate 
as readily (Ambrose and Clanton, 2004). An inflammatory 
response was observed in soft tissue collected from around 
the defect site in all groups. Macrophages attracted by the 
presence of a foreign body can mediate the biodegradation 
of the materials by phagocytosis (Xia and Triffitt, 2006; 
Anderson and Shive, 2012) and are also essential for 
effective tissue regeneration as they clear cellular debris 
and encourage the growth of blood vessels and therefore 
restore a vital blood supply.
 Bone ingrowth is thought to be directly linked to 
porosity and pore size (Feng et al., 2011). Porosity of the 
scaffold material in vivo, both with and without antibiotics, 
was approximately 25 % with pore sizes ranging 
from 162-222 μm and therefore within the published 
osteoconductive range (von Doernberg et al., 2006; Bignon 
et al., 2011), although pore sizes of greater than 300 μm 
are thought to allow greater penetration of mineralised 
tissue (Jones et al., 2004). Microporosity (pores ≤5 µm) 
has been shown to be essential for the bioresorbability of 
the material, whilst macroporosity (pores ≥ 100 µm) is 
involved in osteoconductivity (Hannink and Arts, 2011). 
Larger pores facilitate enhanced bioactivity but reduce 
PLGA/PEG bridging points per unit area and in turn 
mechanical strength (Karageorgiou and Kaplan, 2005). 
A high pore volume facilitates the circulation of body 
fluids and therefore increases the potential for the firm 
attachment of new bone tissue (Blokhuis et al., 2000). The 
interconnectivity of pores has also been shown to have a 
significant effect on bone growth within a scaffold material 
(Lu et al., 1999), but was not investigated in this study.
 New bone ingrowth into the defects of sheep sacrificed 
at 13 weeks showed no significant difference, suggesting 
that there was no inhibitory effect of the antibiotic 
combination on osteogenesis. An osteoid layer was seen at 
the edges of the mineralised bone and where new immature 
bone was forming. A fibrous collagen plug had filled the 
top portion of the defect, and this was becoming calcified 
and in time may have become mineralised bone (Shearer 
et al., 1992). A review of current literature by Pountos et 
al. (2011) suggested that although there is evidence that 
antibiotics inhibit cell proliferation in vitro (Gogia et al., 
2009), in vivo fracture healing is not impaired (Haleem et 
al., 2004), as was shown in this study.
 Unlike this study, the majority of the literature describes 
the treatment of infection, not its prevention, and the use 
of materials that are either non-biodegradable, contain 
only one antibiotic or do not support bone growth (van 
der Stok et al., 2010; El-Husseiny et al., 2011). PLGA 
and PLA have been used in several studies that have 
been successful in treating infection (Garvin et al., 1994; 
Kanellakopoulou et al., 2000; Liu et al., 2002; Ambrose et 
al., 2004; Koort et al., 2005; Peng et al., 2010; Ambrose et 
al., 2014), but only a single antibiotic has been tested. The 
use of hydroxyapatite (Korkusuz et al., 1993; Shinto et al., 
1992; Itokazu et al., 1997), calcium phosphate (Nandi et 
al., 2008) and calcium sulphate (Turner et al., 2005; Parker 
et al., 2011) in combination with one antibiotic have also 
been shown to treat infection.
 Although this study was designed to test the efficacy 
of the antibiotic impregnated material at preventing 
infection a limitation of this study was the omission of 
a positive (autologous bone graft) and negative control 
(empty defect). This would have allowed us to prove that 
the bone ingrowth seen was truly due to the presence of 
the scaffold material. The only published reference of 
an empty defect (5 mm diameter x 15 mm height) in the 
sheep femoral condyle model stated that an empty defect 
contained 26.9 ±6.4 % at 4 months (van der Pol et al., 
2010).
Conclusions
We have shown that a gradual release of a combination 
of antibiotics over 19-21 days is achievable in vitro from 
a biodegradable scaffold, without any negative effects on 
the mechanical properties of the scaffold. We have further 
shown that the antimicrobial material was able to prevent 
S. aureus infection from establishing in bone defects in 
sheep, whilst supporting a significant amount of new bone 
growth in a 13 week period. Further research is being 
carried out to demonstrate the activity of the biodegradable 
antimicrobial polymer against a wider range of bacteria, 
which in turn may allow the material to be used in the 
earlier treatment of traumatic bone loss with the reduction 
of infective complications, possibly removing the need for 
concurrent systemic therapy, thus reducing adverse events 
and bacterial resistance.
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Discussion with Reviewers
T. Moriarty: How is the effective duration of in vivo 
antibiotic dosing (stated to be 7 days; Campoccia et al., 
2010, text reference) to prevent clinical surgical infection 
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determined since this value seems to be highly variable 
in the literature?
Authors: The length of duration is highly variable as 
there is no evidence in the literature to support a particular 
timescale. For surgical prophylaxis in clean implants 
24 h of antibiotic cover has been shown to be adequate. 
However as we are aiming to prevent infection at a more 
contaminated site in this study it was felt that 7 days would 
be suitable. This was confirmed as an effective duration as 
all sheep that were infected with S. aureus and received 
the antibiotic impregnated scaffold material were found 
to be free of infection at the 2 week and 13 week sacrifice 
time points.
T. Moriarty: Must local osteocyte or osteoblast toxicity 
to drug release be determined in vivo in the wound site 
to ascertain safety? How might local pharmacology be 
assessed?
Authors: There are a range of tests required according 
to the International Standard ISO 10993: Biological 
Evaluation of Medical Devices (Web Ref. D1, additional 
reference). Both cytotoxicity and mutagenicity (ISO 
10993:3) have been carried out on the antibiotic free 
product, and was found to be both non-mutagenic and non-
cytotoxic. Endotoxin testing (ISO 10993:11) has not yet 
been carried out on the product with or without antibiotics, 
but will be carried out during future pre-clinical studies.
 Draft guidance was released by the FDA on antimicrobial 
devices (Web Ref. D2, additional reference). This stated a 
range of tests that should be carried out during pre-clinical 
testing. These include: the identity and formulation of 
antimicrobial agents and accompanying substances; 
concentration of the antimicrobial agent on the device; 
method used to apply the antimicrobial agent to the device; 
mechanism of action of the agent; antimicrobial activity 
spectrum of the agent; release kinetics of the agent from 
the device over time; minimum effective concentration; 
and toxicity of the agent.
 Local pharmacology could be assessed by collecting 
bone, blood and soft tissue samples, both locally and 
systemically, and processing them to be analysed on an 
HPLC to detect the levels of the antibiotics at different time 
points. Recommended methods are published in the British 
Pharmacopeia (Web Ref. D3, additional reference) and in 
ASTM International (Web Ref. D4, additional reference).
T. Moriarty: How do regulatory bodies view the dual 
antibiotic release strategy? Is there an approval route seen 
that would allow this strategy to move forward for clinical 
adoption?
Authors: A regulatory strategy has been created after 
meeting with regulatory consultants. The device is 
classed as a combinational product due to the use of two 
pharmacological registered antibiotics. In the US it will 
be classed by the FDA as a Class III device and in Europe 
by the MHRA as a Class III device.
 For both the FDA and the MHRA the recommended 
bench testing includes in vitro studies to demonstrate the 
effectiveness of the device with relevant clinical isolates 
to show the spectrum and activity of the antibiotics on the 
medical device. The studies must include a comparison of 
the antibiotic impregnated device with the device alone, 
and establish the relationship between the antibiotic 
effectiveness and the effective concentration of the 
antibiotics in the device. Studies must also be carried out to 
look at the elution of the antibiotic over time. In addition, it 
is recommended to conduct tests to assess the antibiotic’s 
effect on the specifications or performance of the device. 
This would include an assessment of material or surface 
changes, and changes to device integrity, stability, and 
mechanical durability.
 European registration will require a design dossier 
covering both the device element and the medicinal 
element. The device element would be assessed by an 
assigned notified body, and the medicinal element would 
be reviewed by the MHRA in the UK. This file would be 
reviewed by a notified body as it is a new pharmaceutical 
application. Clinical evidence will be required for both 
elements, which will involve a formal trial due to two 
antibiotics being used in combination.
 Registration in the USA will require Premarket 
Approval (PMA) as it is a Class III device and would 
be under the jurisdiction of the Office of Combination 
Products (OCP). PMA is the most stringent type of device 
marketing application required by the FDA and would take 
180 days to review.
T. Moriarty: Does sterilisation method affect 1) material 
degradation characteristics, 2) drug potency?
Authors: The method of sterilisation was electron beam 
sterilisation at 25-30 kGy. Published literature states that 
there are several effects of ionising radiation on PLGA, 
although electron beam sterilisation has been reported to 
be less damaging than gamma sterilisation (Nuutinen et 
al., 2002, additional reference). This damage can be a drop 
in the molecular weight and glass transition temperature, a 
loss in the mechanical properties and an increased rate in 
degradation (Loo et al., 2005, additional reference). Tests 
were carried out by the industrial partner, and do show 
that there is a small effect of electron beam sterilisation 
on the scaffold material. The molecular weight, assessed 
by Gel Permeation Chromatography, is approximately 
6 % lower after sterilisation. Previous work carried out 
implanting the same electron beam sterilised scaffold 
material in the calvarial defect of a mouse was successful 
at encouraging bone growth, suggesting no deleterious 
effects of sterilisation (Rahman et al., 2012, text reference). 
Further investigations will be carried out to look at the 
degradation rate.
 In this study, the drug bioavailability would not have 
been affected by sterilisation as the antibiotics were mixed 
with the product after suspension in an autoclaved solution 
of CMC, and did not undergo electron beam sterilisation. 
Ionising radiation is routinely used to sterilise antibiotic 
containing bone cements (Web Ref. D5, additional 
reference) although literature has shown that there may 
be some effects on the degradation and the antimicrobial 
activity of antibiotics, however a dry powder may show 
less of an effect than an aqueous solution (Abuhanoğlu 
and Özer, 2010, additional reference).
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Reviewer III: When do you expect the entire release 
of the antibiotics from the scaffold? Even if no Zone of 
inhibition is formed after 19 days, this does not mean that 
the scaffold is free of Abx.
Authors: Fracture of the remaining polymer and testing for 
zones of inhibition showed no residual activity indicating 
that if any antibiotics remained in the polymer that they 
were below the MIC of the test bacteria. If there were any 
antibiotics trapped within the scaffold material, this study 
has shown that the scaffold material biodegrades before 13 
weeks, and is therefore free of antibiotics at that point. In 
addition, tests could be run on in vitro scaffolds at several 
time points to assess the antibiotic content.
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